Home > Archive > 2011 >

Volume 30, Number 3 (September/October)

Automated Diabetes Management Systems (pages 6-10)

Kevin L. McMahon and Stephen W. Ponder, M.D., C.D.E.

Current strategies for communicating blood glucose data are time-consuming for patients and health-care providers. The authors describe the use of an automated diabetes management system to improve communication and patient outcomes. They provide instructive case studies.
Health services and insurance
Management strategies and toolsStrategies for glycemic control

How to Use Insulin in Type 2 Diabetes Mellitus (pages 17-24)

Ioana Fat, M.D., Simona Ioja, M.D., and Nancy J. Rennert, M.D., F.A.C.E., F.A.C.P.

About half of all patients with Type 2 diabetes will require insulin regardless of adherence to oral medications and self-management recommendations. Drs. Fat, Ioja, and Rennert outline general guidelines for providing insulin therapy to these patients throughout the progression of the disease.
Drug treatmentInsulin

Diabetes and Depression (pages 25-28)

Brad Rzepniewski, L.C.S.W., A.C.T.

Depression is relatively common among diabetes patients and presents additional challenges to treatment. The author offers guidance on screening patients with diabetes for depression and provides suggestions for treating patients who have been diagnosed with both of these conditions.
Complications and comorbiditiesDepression

AIM-HIGH Misses Its Target (pages 29-30)

Charles A. Reasner, M.D.

While small clinical studies suggest that raising HDL cholesterol with niacin can reduce the incidence of cardiovascular events, a recent major study of extended-release niacin plus statin therapy—the AIM-HIGH trial—was stopped early because it did not show this effect. The Editor reviews several of the major recent studies of niacin, ultimately advocating a “middle of the road” approach to prescribing the drug.
Drug treatmentCholesterol-lowering drugs
Complications and comorbiditiesCardiovascular diseaseDyslipidemia